Oramed Pharmaceuticals (ORMP) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Oramed Pharmaceuticals

NasdaqCM•Healthcare•Biotechnology

$5.01+0.08(0.02%)After hours

Market Cap

$204.38M

P/E

1.2x

P/B

0.6x

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

How this company scores

AverageMetricSide Score: 46/100

Strongest: Profitability (17/25); weakest: Cash & Earnings Quality (2/25).

Profitability17/25

Growth12/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality2/25

Strengths

High ROERising earningsInterest easily coveredProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 1.2x5y range 1.2x – 21.3x

Currently below its 8-quarter median.

P/S · 57.4x5y range 18.8x – 248.4x

Currently near its 15-quarter median.

P/B · 0.6x5y range 0.6x – 5.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $204.38M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $-2.00M
Q. Revenue: $0
TTM EBITDA: $-14.52M
TTM Op. Income: $-14.52M
Q. Op. Income: $-2.77M
TTM Net Income: $174.87M
Q. Net Income: $78.16M
EPS: $1.9
Shares Out.: $41.04M

$-2.00M in TTM revenue declined 150.0% YoY, reaching $0 last quarter. TTM EBITDA of $-14.52M and TTM operating income of $-14.52M show growth is flowing through to the bottom line. TTM net income of $174.87M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has fallen for 3 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -276600000.0%
Net Margin: 7815600000.0%

Op. margin of -276600000.0% is down 276599875.6% YoY — costs are rising relative to revenue. Net margin at 7815600000.0% Over the past year, operating margin is down 222257835% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 1.2x
P/S Ratio: N/A
P/B Ratio: 0.6x

At 1.2x P/E, the stock trades below typical market levels. P/S of 0.0x and P/B of 0.6x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 5 quarters, P/E has fallen for 4 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $369.64M
Cash: $15.24M
Long-Term Debt: N/A
Book Value: $317.47M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-200,000
TTM Free Cash Flow: $-5.21M
FCF Margin: N/A
FCF / Net Income: -0.0

TTM FCF of $-5.21M on $-200,000 in operating cash flow. The FCF / Net Income ratio of -0.0x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.